Bellevue Group’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.7M | Sell |
64,412
-665
| -1% | -$361K | 0.75% | 37 |
|
|
2025
Q4 | $37.7M | Sell |
65,077
-41,108
| -39% | -$23.2M | 0.71% | 33 |
|
|
2025
Q3 | $51.5M | Sell |
106,185
-7,359
| -6% | -$3.43M | 1.07% | 25 |
|
|
2025
Q2 | $46M | Buy |
113,544
+49,312
| +77% | +$20.6M | 1.01% | 23 |
|
|
2025
Q1 | $32M | Buy |
64,232
+3,270
| +5% | +$1.77M | 0.72% | 34 |
|
|
2024
Q4 | $31.7M | Buy |
60,962
+7,339
| +14% | +$4.03M | 0.61% | 40 |
|
|
2024
Q3 | $33.2M | Buy |
53,623
+10,997
| +26% | +$6.51M | 0.54% | 56 |
|
|
2024
Q2 | $23.6M | Buy |
42,626
+2,670
| +7% | +$1.53M | 0.38% | 64 |
|
|
2024
Q1 | $23.2M | Buy |
39,956
+4,614
| +13% | +$2.59M | 0.35% | 74 |
|
|
2023
Q4 | $18.8M | Sell |
35,342
-31,126
| -47% | -$15.1M | 0.29% | 77 |
|
|
2023
Q3 | $33.6M | Sell |
66,468
-29,633
| -31% | -$15.8M | 0.54% | 52 |
|
|
2023
Q2 | $50.1M | Buy |
96,101
+9,768
| +11% | +$5.27M | 0.72% | 46 |
|
|
2023
Q1 | $49.8M | Buy |
86,333
+3,004
| +4% | +$1.69M | 0.72% | 48 |
|
|
2022
Q4 | $45.9M | Buy |
83,329
+11,185
| +16% | +$5.93M | 0.61% | 55 |
|
|
2022
Q3 | $36.6M | Buy |
72,144
+326
| +0.5% | +$182K | 0.53% | 57 |
|
|
2022
Q2 | $39M | Sell |
71,818
-815
| -1% | -$449K | 0.55% | 55 |
|
|
2022
Q1 | $42.9M | Sell |
72,633
-25,695
| -26% | -$14.8M | 0.5% | 65 |
|
|
2021
Q4 | $65.6M | Buy |
98,328
+11,449
| +13% | +$7.15M | 0.68% | 52 |
|
|
2021
Q3 | $49.6M | Buy |
86,879
+44,905
| +107% | +$24.6M | 0.5% | 63 |
|
|
2021
Q2 | $21.2M | Buy |
41,974
+5,400
| +15% | +$2.55M | 0.21% | 107 |
|
|
2021
Q1 | $16.7M | Sell |
36,574
-7,881
| -18% | -$3.76M | 0.18% | 106 |
|
|
2020
Q4 | $20.7M | Sell |
44,455
-26,410
| -37% | -$12.4M | 0.24% | 99 |
|
|
2020
Q3 | $31.3M | Buy |
70,865
+1,374
| +2% | +$568K | 0.43% | 62 |
|
|
2020
Q2 | $25.2M | Buy |
69,491
+29,939
| +76% | +$10M | 0.36% | 69 |
|
|
2020
Q1 | $11.2M | Sell |
39,552
-25,245
| -39% | -$7.96M | 0.22% | 79 |
|
|
2019
Q4 | $21.1M | Buy |
64,797
+7,561
| +13% | +$2.29M | 0.33% | 58 |
|
|
2019
Q3 | $16.7M | Buy |
57,236
+212
| +0.4% | +$60.7K | 0.31% | 64 |
|
|
2019
Q2 | $16.7M | Buy |
57,024
+18,166
| +47% | +$5M | 0.29% | 61 |
|
|
2019
Q1 | $10.6M | Buy |
38,858
+2,166
| +6% | +$539K | 0.59% | 50 |
|
|
2018
Q4 | $8.21M | Buy |
36,692
+2,221
| +6% | +$521K | 0.54% | 50 |
|
|
2018
Q3 | $8.41M | Buy |
34,471
+5,340
| +18% | +$1.23M | 0.53% | 56 |
|
|
2018
Q2 | $6.03M | Buy |
29,131
+5,283
| +22% | +$1.12M | 0.51% | 52 |
|
|
2018
Q1 | $4.92M | Sell |
23,848
-1,960
| -8% | -$411K | 0.49% | 54 |
|
|
2017
Q4 | $4.9M | Hold |
25,808
| – | – | 0.51% | 49 |
|
|
2017
Q3 | $4.88M | Buy |
25,808
+11,208
| +77% | +$2.03M | 0.51% | 54 |
|
|
2017
Q2 | $2.55M | Buy |
14,600
+1,600
| +12% | +$269K | 0.3% | 74 |
|
|
2017
Q1 | $2M | Sell |
13,000
-3,000
| -19% | -$459K | 0.27% | 78 |
|
|
2016
Q4 | $2.26M | Hold |
16,000
| – | – | 0.46% | 59 |
|
|
2016
Q3 | $2.54M | Sell |
16,000
-4,000
| -20% | -$616K | 0.46% | 60 |
|
|
2016
Q2 | $2.96M | Hold |
20,000
| – | – | 0.56% | 54 |
|
|
2016
Q1 | $2.83M | Buy |
+20,000
| New | +$2.68M | 0.51% | 67 |
|
Other funds holding TMO
VCM
Bellevue Group's TMO Position: Q1 2026 in Review
Bellevue Group reduced its Thermo Fisher Scientific (TMO) stake by 1% in Q1 2026, selling an estimated $361K and leaving 64,412 shares worth $31.7M. The position accounts for 0.75% of the portfolio, ranked #37.
Bellevue Group first reported a position in TMO in Q1 2016 and has held it in 41 quarters since. The position peaked at $65.6M in Q4 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Bellevue Group held 64,412 shares of Thermo Fisher Scientific worth $31.7M as of Q1 2026.
- Bellevue Group sold 665 Thermo Fisher Scientific shares in Q1 2026, an estimated $361K.
- Thermo Fisher Scientific made up 0.75% of Bellevue Group's portfolio in Q1 2026, its #37 holding.
- Bellevue Group first reported a position in Thermo Fisher Scientific in Q1 2016 and has held it in 41 quarters since.
- Bellevue Group's Thermo Fisher Scientific position peaked at $65.6M in Q4 2021.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.